Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
暂无分享,去创建一个
B. Al-Lazikani | Myles A Brown | S. Ficarro | G. Adelmant | J. Marto | X. Salvatella | G. Nienhaus | J. Troppmair | U. Strähle | S. Bräse | B. Luy | H. Puchta | O. Armant | N. Jung | T. Westerling | J. D. de Bono | C. Muhle-Goll | A. Sharp | Laura Cato | I. Figueiredo | R. Riisnaes | V. Gourain | D. Nava Rodrigues | A. Cato | A. Neeb | D. Dolling | Linxiao Yang | Friedrich Fauser | Víctor Buzón | P. Rescigno | Nane C. Kuznik | E. A. Ntim | Jennifer Wu | Jaice T Rottenberg | L. Shatkina | C. Ester | Myles A. Brown | Daniel Nava Rodrigues | Stefan Bräse
[1] Tao Liu,et al. ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline , 2016, BMC Bioinformatics.
[2] Shihua Sun,et al. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer , 2016, European urology.
[3] X. Salvatella,et al. EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor. , 2016, ACS chemical biology.
[4] David Balchin,et al. In vivo aspects of protein folding and quality control , 2016, Science.
[5] R. Aebersold,et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. , 2016, Cancer cell.
[6] H. Stuppner,et al. The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ , 2016, Oncogenesis.
[7] Amanda C. Schierz,et al. canSAR: an updated cancer research and drug discovery knowledgebase , 2015, Nucleic Acids Res..
[8] R. Morimoto,et al. The biology of proteostasis in aging and disease. , 2015, Annual review of biochemistry.
[9] Robert J. Weatheritt,et al. How do disordered regions achieve comparable functions to structured domains? , 2015, Protein science : a publication of the Protein Society.
[10] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[11] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[12] F. Claessens,et al. Androgen receptor antagonists for prostate cancer therapy. , 2014, Endocrine-related cancer.
[13] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[14] Bonnie Berger,et al. A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways , 2014, Cell.
[15] Myles A Brown,et al. Coregulator Control of Androgen Receptor Action by a Novel Nuclear Receptor-binding Motif* , 2014, The Journal of Biological Chemistry.
[16] S. Plymate,et al. Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit , 2013, Clinical Cancer Research.
[17] Gerhard Wolber,et al. Isolation of a Novel Thioflavin S–Derived Compound That Inhibits BAG-1–Mediated Protein Interactions and Targets BRAF Inhibitor–Resistant Cell Lines , 2013, Molecular Cancer Therapeutics.
[18] R. Ni,et al. Overexpressed nuclear BAG‐1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin , 2013, Journal of cellular biochemistry.
[19] H. Klocker,et al. Enhanced Inhibition of Prostate Tumor Growth by Dual Targeting the Androgen Receptor and the Regulatory Subunit Type Iα of Protein Kinase A in Vivo , 2013, International journal of molecular sciences.
[20] E. Powers,et al. Diversity in the origins of proteostasis networks — a driver for protein function in evolution , 2013, Nature Reviews Molecular Cell Biology.
[21] Carlos Caldas,et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. , 2013, Cell reports.
[22] W. Wenzel,et al. A Peptidic Unconjugated GRP78/BiP Ligand Modulates the Unfolded Protein Response and Induces Prostate Cancer Cell Death , 2012, PloS one.
[23] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[24] P. Nelson,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.
[25] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[26] Erin L. Doyle,et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.
[27] Yi Zhang,et al. Affinity and Chemical Enrichment for Mass Spectrometry-Based Proteomics Analyses , 2011 .
[28] David E. Williams,et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.
[29] Yi Zhang,et al. multiplierz: an extensible API based desktop environment for proteomics data analysis , 2009, BMC Bioinformatics.
[30] Clifford A. Meyer,et al. Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.
[31] Jignesh R. Parikh,et al. mzAPI: a new strategy for efficiently sharing mass spectrometry data , 2009, Nature Methods.
[32] S. Ficarro,et al. Improved electrospray ionization efficiency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells. , 2009, Analytical chemistry.
[33] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[34] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[35] H. Dyson,et al. Linking folding and binding. , 2009, Current opinion in structural biology.
[36] Y. Li,et al. Different BAG-1 isoforms have distinct functions in modulating chemotherapeutic-induced apoptosis in breast cancer cells , 2009, Acta Pharmacologica Sinica.
[37] A. C. Williams,et al. BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. , 2008, Carcinogenesis.
[38] I. McEwan,et al. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. , 2008, Biochemistry.
[39] Frank Claessens,et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling , 2008, Nuclear receptor signaling.
[40] Phuong Nguyen,et al. A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.
[41] K. Pienta,et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.
[42] T. Visakorpi,et al. Overexpression and gene amplification of BAG‐1L in hormone‐refractory prostate cancer , 2007, The Journal of pathology.
[43] John Calvin Reed,et al. Expression of BAG‐1 protein correlates with aggressive behavior of prostate cancers , 2006, The Prostate.
[44] Fred Schaufele,et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] Wayne Boucher,et al. The CCPN data model for NMR spectroscopy: Development of a software pipeline , 2005, Proteins.
[46] H. Dyson,et al. Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.
[47] A. L. Burlingame. Biological mass spectrometry , 2005 .
[48] M. Mayer,et al. Hsp70 chaperones: Cellular functions and molecular mechanism , 2005, Cellular and Molecular Life Sciences.
[49] A. Kristina Downing,et al. Protein NMR techniques , 2004 .
[50] R. Morimoto,et al. Molecular chaperones and the stress of oncogenesis , 2004, Oncogene.
[51] Bruce A Johnson,et al. Using NMRView to visualize and analyze the NMR spectra of macromolecules. , 2004, Methods in molecular biology.
[52] Ruo-Pan Huang,et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors , 2004, Breast Cancer Research and Treatment.
[53] Michael D. Abràmoff,et al. Image processing with ImageJ , 2004 .
[54] H. Klocker,et al. The Cochaperone Bag-1L Enhances Androgen Receptor Action via Interaction with the NH2-Terminal Region of the Receptor , 2003, Molecular and Cellular Biology.
[55] P. Townsend,et al. The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription , 2003, Oncogene.
[56] P. Townsend,et al. BAG-1 prevents stress-induced long-term growth inhibition in breast cancer cells via a chaperone-dependent pathway. , 2003, Cancer research.
[57] P. Townsend,et al. BAG-1: a multifunctional regulator of cell growth and survival. , 2003, Biochimica et biophysica acta.
[58] S. Alberti,et al. BAG-1—a nucleotide exchange factor of Hsc70 with multiple cellular functions , 2003, Cell stress & chaperones.
[59] Hongyu Liu,et al. Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line , 2002, Oncogene.
[60] R. Frank. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. , 2002, Journal of immunological methods.
[61] Lars Packschies,et al. Tuning of chaperone activity of Hsp70 proteins by modulation of nucleotide exchange , 2001, Nature Structural Biology.
[62] John Calvin Reed,et al. Structure-Function Analysis of Bag1 Proteins , 2001, The Journal of Biological Chemistry.
[63] Marnie L. Havert,et al. Structural analysis of BAG1 cochaperone and its interactions with Hsc70 heat shock protein , 2001, Nature Structural Biology.
[64] Holger Sondermann,et al. Structure of a Bag/Hsc70 Complex: Convergent Functional Evolution of Hsp70 Nucleotide Exchange Factors , 2001, Science.
[65] S. Tang,et al. Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. , 2000, International journal of cancer.
[66] John Calvin Reed,et al. BAG1L Enhances Trans-activation Function of the Vitamin D Receptor* , 2000, The Journal of Biological Chemistry.
[67] Z. Ding,et al. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells. , 2000, Biochemical and biophysical research communications.
[68] M. Blum,et al. Isoform-specific expression of BAG-1 in mouse development , 2000, Mechanisms of Development.
[69] Martin R. Schneider,et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.
[70] Christian Griesinger,et al. Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients , 1999 .
[71] Z. Ding,et al. Human BAG-1/RAP46 protein is generated as four isoforms by alternative translation initiation and overexpressed in cancer cells , 1998, Oncogene.
[72] J C Reed,et al. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. , 1998, Cancer research.
[73] J C Reed,et al. BAG-1L Protein Enhances Androgen Receptor Function* , 1998, The Journal of Biological Chemistry.
[74] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.
[75] S Detre,et al. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.
[76] G. Jenster,et al. Identification of Two Transcription Activation Units in the N-terminal Domain of the Human Androgen Receptor (*) , 1995, The Journal of Biological Chemistry.